This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vertex Has the Potential to Go Vertical

NEW YORK (TheStreet) -- After the entire biotech sector posted more than 60% gains in 2013, which more than doubled the performance of the S&P 500, there's little debate that biotech stocks were among the Street's favorites last year. In 2014, however, this means there are very few biotech bargains left. Yet Vertex Pharmaceuticals (VRTX - Get Report) seems to fit that bill.

As intimately as I've followed this sector last year, I still can't forgive myself for passing up on this company. What I notice now is a company with a strong and distinguishing product portfolio that has the potential to dominate its market. And with a bit of luck in clinical trials, the company will be able to generate close to $6 billion to $10 billion in annual revenue.

Vertex's key drug is Kalydeco, used to fight cystic fibrosis in a relatively small group of patients with a specific genetic mutation. Unlike older drugs which only treat the symptoms of cystic fibrosis, Kalydeco is revolutionary because it addresses the underlying condition of the disease. Even better, the company's is making progress on developing additional cystic fibrosis drugs, which will be used in combinations to benefit larger groups of patients with other genetic mutations. What I like best about Vertex is that the company has the potential to corner the market for the treatment of a disease that is still lethal and remains one of the most common chronic lung illnesses in children and young adults.

The Street has caught on. Last year, Vertex shares rose almost 80%. Understandably investors are taking a more cautious, if not skeptical, approach to Vertex this year. The company's success in 2014 will hinge largely on the outcome of two clinical studies testing the combination of two cystic fibrosis drugs. The company is expected to announce results from these clinical studies in the middle of the year. While I can understand investors being worried about the result from this combination approach to treating cystic fibrosis, I don't believe this is the right time to lack confidence in Vertex's management.

[Read: Apple and IBM Have Must-See Charts]

On Wednesday, Vertex will report fourth-quarter and full-year 2013 earnings. The Street is looking for a loss of 38 cents per share on revenue of $229 million, which would represent a year-over-year revenue decline of 31%. Sales of Vertex's hepatitis C drug have declined due to competition from newer medicines in that disease, but investors are focusing more now on the company's cystic fibrosis drugs, which don't have near-term competition. Revenue and near-term profitability do not drive this stock. What's important for Vertex is the further development of its cystic fibrosis pipeline, and in that regard, I like Vertex.

All told, Vertex will be one of the best stocks to follow in biotech. And the results of the company's testing will certainly have a meaningful impact on growth expectations and where the stock ultimately goes. Although risks remain, absent a comparable alternative, the Street has no choice but to love Vertex for the foreseeable future.

At the time of publication, the author held no position in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
VRTX $129.36 -2.78%
AAPL $118.30 0.42%
FB $104.24 -1.15%
GOOG $742.60 -1.02%
TSLA $230.26 -0.58%


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs